Akari Therapeutics (FRA:CLA) Change In Receivables : €0.00 Mil (TTM As of Jun. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics Change In Receivables?

Akari Therapeutics's change in receivables for the quarter that ended in Jun. 2024 was €0.00 Mil. It means Akari Therapeutics's Accounts Receivable stayed the same from Mar. 2024 to Jun. 2024 .

Akari Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was €0.00 Mil. It means Akari Therapeutics's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Akari Therapeutics's Accounts Receivable for the quarter that ended in Jun. 2024 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Akari Therapeutics's liquidation value for the three months ended in Jun. 2024 was €-4.28 Mil.

Akari Therapeutics Change In Receivables Historical Data

The historical data trend for Akari Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Change In Receivables Chart

Akari Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

1.60

Akari Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Dec23	Mar24	Jun24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Akari Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Akari Therapeutics (FRA:CLA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Akari Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Akari Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Akari Therapeutics's liquidation value for the quarter that ended in Jun. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3.88	-	8.156	+	0.75 * 0	+	0.5 * 0
=	-4.28

Akari Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Akari Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

AKTX:USA

Address

75/76 Wimpole Street, London, GBR, W1G 9RT

Website

https://www.akaritx.com

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. It operates mainly in United States and United Kingdom.